GENITOURINARY CANCERS

Enzalutamide's efficacy is supported by preference studies and a MAIC, helping doctors and patients make informed treatment choices.

Without head-to-head trials, doctors balance MAIC efficacy data with factors like cost and safety to choose the best ARPI for each patient.

A statistical analysis (MAIC) of the ARCHES and ARANOTE studies suggests enzalutamide is more effective at delaying disease progression.

With no head-to-head trials for ARPIs, physicians use methods like MAIC to indirectly compare efficacy and safety, guiding treatment decisions.

Enzalutamide and other ARPIs are key in treating metastatic prostate cancer by blocking androgen receptors, improving patient survival rates.

FDA accepts a new formulation of piflufolastat F 18, enhancing prostate cancer imaging access and efficiency, with a target action date of March 2026.

UroGen Pharma's ENVISION trial reveals promising long-term efficacy of intravesical mitomycin for treating low-grade bladder cancer, offering a non-surgical option.

The KEYNOTE-426 trial confirms pembrolizumab plus axitinib's long-term effectiveness for advanced kidney cancer, revealing insights into predictive biomarkers for treatment response.

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit.

Home-based mitomycin treatment shows promise for bladder cancer patients, enhancing convenience and reducing healthcare burdens while maintaining safety and efficacy.

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic benefits during treatment.

A recent study reveals low rates of upper tract urothelial carcinoma in non-muscle-invasive bladder cancer, prompting a reevaluation of routine imaging practices.

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to therapy.

A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for patients with limited options.

The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative drug delivery.

The PROGRxN-BCa study, led by Jethro C.C. Kwong, showcases a major advancement in predicting disease progression in non–muscle-invasive bladder cancer through artificial intelligence (AI).

Researchers explored a compelling new angle on the use of rectal spacers during prostate cancer radiotherapy, and emerging evidence suggests their benefits may extend further.

A new study reveals that rectal spacers during prostate cancer radiation therapy significantly reduce long-term erectile dysfunction rates, enhancing patient outcomes.

Mack Roach III, MD, discusses the development and evaluation of a multimodal AI algorithm designed to predict prostate cancer outcomes and its performance across racial subgroups.

Joseph Jacob, MD, discusses the promising impact of TAR-200.

The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, AI-driven urine test.

A groundbreaking trial for TYRA-300, an oral FGFR3 inhibitor, aims to transform treatment for patients with low-grade intermediate-risk bladder cancer.

Biren Saraiya, MD, discusses how he sees findings from the phase 3 AMPLITUDE trial being incorporated into clinical practice for the treatment of metastatic castration-sensitive prostate cancer.

Biren Saraiya, MD, provides background on the phase 3 AMPLITUDE study evaluating niraparib plus abiraterone acetate in metastatic castration-sensitive prostate cancer.